The advertising wall

Article 88 of Directive 2001/83/EC prohibits advertising prescription-only medicines to the general public across the EU, and the UK mirrors it in the Human Medicines Regulations 2012. That much is boring and settled. What matters commercially is that four regulators have spent 2025 and 2026 pushing the definition of advertising outward, and each pushed it somewhere different.

If you take one thing from this page: the ban protects the public. Marketing to pharmacists, prescribers and clinics is expressly permitted everywhere. That asymmetry is the single most exploitable fact in this atlas.

Reg. 284 of the HMR 2012 bans publishing an advertisement likely to lead to the use of a POM. Reg. 303 makes breach a criminal offence carrying up to two years on indictment. That is the strongest sanction anywhere in this atlas.

CAP monitored 95,000 unique ads across Google, Meta and TikTok with AI scanning and drove the breach rate from 7% in February 2025 to 1% after the second joint enforcement notice. The ASA banned 13 posts from Voy, Zava, MedExpress and UK Meds Direct in February 2026 and stated plainly that affiliate marketing is not a loophole, the poster and the business are both liable.

HWG §10 restricts Rx advertising to Fachkreise. On 26 March 2026 the BGH ruled (I ZR 74/25) that describing the conditions a prescription drug class treats, and enabling a treatment request off the back of it, is unlawful public advertising even without naming a product: and expressly rejected the "we only connect patients to doctors" defence. Combined with the March 2025 Munich injunction on questionnaire-only obesity prescribing, the German corridor is now very narrow.

On 29 April 2026 ANSM sanctioned Novo Nordisk €1,783,838 and Eli Lilly France €108,766 for obesity disease-awareness campaigns judged to be indirect POM advertising. If awareness marketing by the manufacturer is worth €1.78m in fines, a brand has no room at all. ANSM has separately referred cases to prosecutors and opened proceedings against around ten online platforms.

The Dutch inspectorate has fined newspapers roughly twenty times between 2023 and 2025 for articles about Ozempic and Wegovy, with DPG Media titles taking €51,000 and €48,450. Swissmedic went further, intervening against Ringier, NZZ and 20 Minuten in January 2025 over ordinary journalistic coverage, on the theory that mere information counts as advertising if it can influence consumption behaviour.

The common assumption that Switzerland, being outside the EU, is more permissive on DTC advertising is simply wrong. It is stricter in practice.

On 19 June 2025 the CJEU ruled Poland's absolute ban on pharmacy advertising breaches EU freedom-of-establishment law. GIF's own chief now calls the ban fiction and around 11m PLN of fines face refund. Note what changed and what did not: the pharmacy-advertising ban loosened; the EU-wide prohibition on advertising prescription medicines to the public is untouched.

Consistently across markets, the permitted zone is a service, not a product: "a weight management service", "doctor-led obesity treatment", a programme with a named clinical standard. What is banned, consistently: naming the drug or molecule, euphemisms that unambiguously point at it, images of pens or vials, prices, before-and-after content tied to treatment, influencer and affiliate promotion, and discount or referral codes.

And the exception worth building a business on: none of this restricts what you say to healthcare professionals.